---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-21-017524"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:27:35.841044+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Charles River previews 2022: low-double-digit organic revenue growth, margin expansion, 9% capex

## Summary
- Expects low-double-digit organic revenue growth in 2022 driven by sustained robust demand.
- Non-GAAP operating margin improvement targeted towards ~22.5% by 2024.
- Staffing levels increased ahead of plan; compensation expected to be headwind in 2022.
- Capital expenditure guided at ~9% of total revenue in 2022, mainly for Safety Assessment capacity.
- Outlook presented at Credit Suisse 30th Annual Healthcare Conference on Nov 9, 2021.

## SEC filing metadata
- accession: 0000950103-21-017524
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000095010321017524/0000950103-21-017524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000095010321017524/dp161446_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-21-017524
- JSON: https://secwatch.observer/filing/0000950103-21-017524.json
- Plain text: https://secwatch.observer/filing/0000950103-21-017524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.